Oesophageal cancer

EC Smyth, J Lagergren, RC Fitzgerald… - Nature reviews Disease …, 2017 - nature.com
Oesophageal cancer is the sixth most common cause of cancer-related death worldwide
and is therefore a major global health challenge. The two major subtypes of oesophageal …

Improving outcomes in patients with oesophageal cancer

MA Shah, N Altorki, P Patel, S Harrison… - Nature Reviews …, 2023 - nature.com
The care of patients with oesophageal cancer or of individuals who have an elevated risk of
oesophageal cancer has changed dramatically. The epidemiology of squamous cell and …

Oesophageal cancer

J Lagergren, E Smyth, D Cunningham, P Lagergren - The Lancet, 2017 - thelancet.com
Oesophageal cancer is a clinically challenging disease that requires a multidisciplinary
approach. Extensive treatment might be associated with a considerable decline in health …

Advances in the curative management of oesophageal cancer

JC Bolger, CL Donohoe, M Lowery… - British Journal of …, 2022 - nature.com
The incidence of oesophageal cancer, in particular adenocarcinoma, has markedly
increased over the last four decades with adenocarcinoma becoming the dominant subtype …

Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal …

F Tixier, CC Le Rest, M Hatt… - Journal of Nuclear …, 2011 - jnm.snmjournals.org
18F-FDG PET is often used in clinical routine for diagnosis, staging, and response to therapy
assessment or prediction. The standardized uptake value (SUV) in the primary or regional …

Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer

WH Allum, SP Stenning, J Bancewicz… - Journal of clinical …, 2009 - ascopubs.org
Purpose OEO2 is a randomized, controlled trial of preoperative chemotherapy in patients
undergoing radical surgery for esophageal cancer. Random assignment was to surgery …

Cancer stem cell‐platelet hybrid membrane‐coated magnetic nanoparticles for enhanced photothermal therapy of head and neck squamous cell carcinoma

LL Bu, L Rao, GT Yu, L Chen, WW Deng… - Advanced Functional …, 2019 - Wiley Online Library
Cell membrane–based nanosystems with desirable characteristics have been studied
extensively for many therapeutic applications. However, current research has focused on …

Myeloid‐derived suppressor cell membrane‐coated magnetic nanoparticles for cancer theranostics by inducing macrophage polarization and synergizing …

GT Yu, L Rao, H Wu, LL Yang, LL Bu… - Advanced Functional …, 2018 - Wiley Online Library
A major challenge for traditional cancer therapy, including surgical resection,
chemoradiotherapy, and immunotherapy, is how to induce tumor cell death and leverage the …

Randomized phase II study of pet response–adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial

KA Goodman, FS Ou, NC Hall… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE To evaluate the use of early assessment of chemotherapy responsiveness by
positron emission tomography (PET) imaging to tailor therapy in patients with esophageal …

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

F Lordick, K Ott, BJ Krause, WA Weber, K Becker… - The lancet …, 2007 - thelancet.com
Background In patients with locally advanced adenocarcinoma of the oesophagogastric
junction (AEG), early metabolic response defined by 18-fluorodeoxyglucose-PET ([18 F] …